Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: Ian@SI who wrote (9330)	10/23/2003 6:29:38 PM
From: Biomaven	Respond to of 52153

Disease will usually be diagnosed only after the abnormal vessels grow behind the retina, leak, and scar the macula. At this point, Visudyne is the only treatment that gets rid of the existing abnormal blood vessels thus stopping the scarring of the macula. A VEGF could then prevent more abnormal growth. I guess that remains to be seen. The squalamine results from Genaera tend to indicate that you can actually get regression of the blood vessels (otherwise how would you get improvement?), and I wouldn't be surprised if REGN's VEGF trap does the same. Peter